Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Krystal Biotech Inc maintains a gross margin of 93.85%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 41.33%, while the net margin is 47.99%. These profitability ratios, combined with a Return on Equity (ROE) of 18.91%, provide a clear picture of how effectively KRYS converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, KRYS competes directly with industry leaders such as HALO and AXSM. With a market capitalization of $7.57B, it holds a significant position in the sector. When comparing efficiency, KRYS's gross margin of 93.85% stands against HALO's 77.39% and AXSM's 92.89%. Such benchmarking helps identify whether Krystal Biotech Inc is trading at a premium or discount relative to its financial performance.
